Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Kswdeluxon Dec 28, 2021 5:36pm
175 Views
Post# 34266138

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Recent CMO promotion/ announcement

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Recent CMO promotion/ announcement

inthno wrote:
Just asking and sorry I missed it but could you please direct me to the agreement that states onc cannot release final results until approved by Roche....there has been so many misdirections on the board stating many different times that we have had the final results and thus now the contradiction.

 

Unfortuately, this is my exact issue with these conference calls, fire side chats and BNN interviews. There are all kinds of significant comments made that are not permenantly captured.

Just like this last CC, they stated,
"results exceeded expectations by statistical significance", but a few months later the audio CC is deleted from the website and no record of those comments.

AWARE-1 was announced Feb 11, 2019.

The comments regarding Not releasing AWARE-1 data until Roche's final review was during on of the following conference calls. That is the best I can do for you.


Some here seem to suggest an additional cohort was added to AWARE-1, but I canot confirm.

AWARE-1 was set up to confirm the biomarker, but ONC has not yet come out and stated that they have confirmed the biomarker. Yet, Roche engages in GOBLET to try to confirm similar biomarkers observed in previous trials.
So, the biomarkers in AWARE-1 must exist, or why look for similar biomarkers in GOBLET.

So it would seem there is more data to come from AWARE-1, basically the conclusion of the biomarkers.

 

<< Previous
Bullboard Posts
Next >>